Rimegepant ndi gawo laling'ono loletsa mamolekyucalcitoningene-related peptide (CGRP) receptor yomwe imalepheretsa zochita za CGRP, vasodilator yamphamvu yomwe amakhulupirira kuti imathandizira kumutu kwa mutu wa migraine.Rimegepant amavomerezedwa kuti azichiza pachimake migraine.M'mayesero azachipatala, rimegepant nthawi zambiri amalekerera bwino pakangochitika kukwera kwa serum aminotransferase kwakanthawi panthawi ya chithandizo ndipo popanda milandu yodziwika bwino yachiwindi.

Rimegepant ndi mdani wapakamwa wa CGRP receptor yopangidwa ndi Biohaven Pharmaceuticals.Adalandira chivomerezo cha FDA pa February 27, 2020 pakuchiza kwa mutu waching'alang'ala.Ngakhale kuti otsutsa angapo a CGRP ndi cholandirira chake avomerezedwa kuti alandire chithandizo cha migraine (mwachitsanzo [erenumab], [fremanezumab], [galcanezumab]), rimegepant ndi [ubrogepant] ndi mamembala okha a gulu la "gepants" lamankhwala omwe atsala pang'ono kukula, ndi okhawo omwe amatsutsana ndi CGRP omwe ali ndi bioavailability wapakamwa.Muyezo wamakono wa chithandizo cha migraine umaphatikizapo chithandizo chochotsa mimba ndi "triptans", monga [sumatriptan], koma mankhwalawa amatsutsana ndi odwala omwe ali ndi matenda a cerebrovascular ndi mtima chifukwa cha vasoconstrictive katundu wawo.Kutsutsana kwa njira ya CGRP kwakhala cholinga chofuna chithandizo cha migraine chifukwa, mosiyana ndi ma triptans, otsutsana ndi CGRP pakamwa alibe mawonekedwe a vasoconstrictive ndipo motero ndi otetezeka kuti agwiritsidwe ntchito kwa odwala omwe ali ndi zotsutsana ndi mankhwala ochiritsira.

Rimegepant ndiCalcitoninPeptide Receptor Antagonist yokhudzana ndi Gene.Njira ya zochita za rimegepant ndi mongaCalcitoninPeptide Receptor Antagonist yokhudzana ndi Gene.